Overcoming the limits of lentivirus: de-risk cell therapy development with non-viral genome engineering
Sponsor
.png "https://www.bio-techne.com/research-areas/cell-and-gene-therapy"){kind=logo}
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Viral-based gene transfer introduces both safety risks and logistical challenges to scaling cell therapies, including high costs, long manufacturing times, and supply chain instability. Many developers are therefore seeking alternative approaches to control manufacturing costs and get therapies to market faster.
Non-viral gene delivery systems, such as the TcBuster™ transposon system, offer a highly cost-effective alternative to lentiviral vectors. The ability to safely and stably integrate large DNA cargos at high efficiency makes non-viral gene delivery an exciting option for CAR-T and CAR-NK cell therapies stem cell-based therapy development.
The logistical benefits of non-viral genome engineering include shorter, simpler cell manufacturing processes and lower cost per patient. But how does it perform compared to lentivirus?
In this webinar, Miles Smith, Genome Engineering Product Manager at Bio-Techne will present data comparing the performance of non-viral and lentiviral-based gene delivery systems in primary human T cells, including cargo capacity, integration efficiency and safety profile, cell expansion, cell phenotype, and cytotoxicity.
Join this webinar for case studies showing how:
- A non-viral system, TcBuster, outperforms lentivirus when inserting larger constructs into primary human T cells
- T cells were modified by both systems and expanded to full confluency
- Copy number and site integration analysis in T cells showed a lower potential for gene disruption
- TcBuster-modified T cells contained a significantly higher percentage of stem cell memory T cells
- Both gene delivery systems were similarly efficacious against CD19-expressing target cells
SPEAKERS
You might also like
Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy
Clinical-scale non-viral gene edited CAR-NK cells for cell therapy
Development of a non-viral gene delivery platform for CAR-T manufacturing
